All In Biotech

NDA 214096 · Emd Serono INC

Tepmetko

Tepotinib Hydrochloride · Oral

NovelAccelerated approvalPriority reviewOrphan

CDER novel approval, Feb 3, 2021: To treat non-small cell lung cancer

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Feb 3, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

29

1 Phase 3, 6 recruiting

FAERS reports

691

489 serious, 163 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 17, 2025.

TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. ( 1 )

Mechanism: Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations. Tepotinib inhibits hepatocyte growth factor (HGF)-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways. Tepotinib also inhibited melatonin 2 and imidazoline 1 receptors at clinically achievable concentrations. In vitro, tepotinib inhibited tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells. In mice implanted with tumor cell lines with oncogenic activation of MET, including MET ex14 skipping...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 15, 2024 Supplement 3 · Efficacy OrphanLabelLetterReview
  • Feb 3, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • TEPMETKO · TEPOTINIB HYDROCHLORIDE EQ 225MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tepotinib" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death114
  • oedema66
  • diarrhoea58
  • oedema peripheral58
  • fatigue56
  • renal impairment56
  • off label use55
  • nausea44
  • disease progression43
  • peripheral swelling39
  • decreased appetite27
  • blood creatinine increased24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20204
202169
202281
2023183
202492
2025105
2026157

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tepmetko (Tepotinib HCl)

2024 spending

$40.6M

Beneficiaries

399

1,914 claims

Per beneficiary

$101,670

$404.39 per unit

View as table
YearSpending
2020$0
2021$5,416,101
2022$12,150,180
2023$22,472,804
2024$40,566,269

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: Emd Serono INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.